INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 11, Issue 8- 2024

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.08.003

Free Radical-Mediated Inflammation in Sickle Cell Disease: A Review

***Emmanuel Ifeanyi Obeagu**
Department of Medical Laboratory Science, Kampala International University, Uganda
*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

Sickle Cell Disease (SCD) is a hereditary blood disorder marked by the production of hemoglobin S (HbS), leading to red blood cell sickling, chronic hemolysis, and vaso-occlusive events. A central feature of SCD pathology is the role of free radical-mediated inflammation, which significantly exacerbates disease severity. Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), are generated in excess due to continuous oxidative stress from hemolysis and tissue ischemia. This review explores how free radicals contribute to inflammation in SCD by inducing oxidative damage, activating inflammatory pathways, and disrupting endothelial function. The review delves into the mechanisms by which ROS and RNS drive inflammatory responses, including the oxidative modification of cellular components, activation of pro-inflammatory signaling pathways, and endothelial dysfunction. These processes lead to the amplification of inflammation, which contributes to the clinical manifestations of SCD, such as pain crises, organ damage, and increased infection risk. The impact of free radical-mediated inflammation on disease outcomes underscores the importance of addressing oxidative stress in therapeutic strategies.

Keywords: Oxidative Stress, Free Radicals, Inflammation, Sickle Cell Disease, Reactive Oxygen Species

Introduction

Sickle Cell Disease (SCD) is a genetic blood disorder resulting from a mutation in the β-globin gene, leading to the production of hemoglobin S (HbS). This abnormal hemoglobin causes red blood cells (RBCs) to adopt a rigid, sickle-shaped morphology under low oxygen conditions. The sickling of RBCs leads to a cascade of pathological events, including hemolysis, vaso-occlusion, and chronic inflammation. The interplay between oxidative stress and inflammation is a critical component of SCD pathophysiology, significantly influencing disease progression and patient outcomes.[1-2] Central to the inflammatory process in SCD is the role of free radicals—reactive molecules that can cause extensive damage to cellular components. Free radicals, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), are produced in excess due to the continuous breakdown of RBCs and the subsequent release of heme and other pro-oxidant factors. These free radicals interact with cellular macromolecules, leading to oxidative stress and inflammation, which perpetuate the disease's clinical manifestations.[3-5] ROS, such as superoxide anions ($O_2^{\bullet-}$), hydrogen peroxide (H_2O_2), and hydroxyl radicals (•OH), are generated primarily through enzymatic processes like those involving NADPH oxidase. RNS, including nitric oxide (NO) and peroxynitrite ($ONOO^-$), are formed through reactions between NO and superoxide radicals. The overproduction of these reactive species contributes to the oxidative damage observed in SCD, affecting not only the RBCs but also various tissues and organs throughout the body.[6-8] The oxidative modifications caused by free radicals can activate several inflammatory pathways. For instance, oxidative damage to cellular proteins, lipids, and DNA can generate damage-associated molecular patterns (DAMPs), which activate pattern recognition receptors (PRRs) and trigger inflammatory responses. Additionally, free radicals can stimulate the activation of transcription factors like nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1), leading to the upregulation of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.[9-11] Endothelial dysfunction is another significant consequence of oxidative stress in SCD. ROS reduce the bioavailability of nitric oxide (NO), a critical molecule for maintaining endothelial integrity and vascular function. The decreased NO levels and increased oxidative stress lead to endothelial activation, characterized by the increased expression of adhesion molecules and the promotion of leukocyte adhesion. This endothelial dysfunction contributes to the vaso-occlusive crises that are a hallmark of SCD.[12-14] The clinical manifestations of SCD are profoundly influenced by the interplay between oxidative stress and inflammation. Pain crises, organ damage, and increased infection risk are exacerbated by the chronic inflammatory state driven by free radicals. Understanding these mechanisms is essential for developing effective treatments that address both oxidative stress and inflammation in SCD.[15-16]

Free Radicals in Sickle Cell Disease

In Sickle Cell Disease (SCD), the presence of abnormal hemoglobin S (HbS) leads to a cascade of pathological processes that significantly impact the body's physiological balance. Central to the progression of SCD is the role of free radicals, particularly reactive oxygen species (ROS) and reactive nitrogen species (RNS), which contribute to oxidative stress and inflammation. The generation and accumulation of these free radicals are a direct consequence of the chronic hemolysis and vaso-occlusive events characteristic of SCD.[17-18] In SCD, the sickling of red blood cells (RBCs) induces continuous hemolysis, which releases heme and iron into the bloodstream. This release initiates a series of oxidative reactions. Free radicals, including superoxide anions ($O_2^{\bullet-}$), hydrogen peroxide (H_2O_2), and hydroxyl radicals (•OH), are produced predominantly through the activity of enzymes like NADPH oxidase. These ROS are highly reactive and can damage cellular structures, including lipids, proteins, and nucleic acids. Alongside ROS, reactive nitrogen species (RNS), such as nitric oxide (NO) and peroxynitrite ($ONOO^-$), are formed when NO reacts with superoxide radicals. The elevated levels of both ROS and RNS

exacerbate oxidative stress and contribute to the chronic inflammatory state observed in SCD.[19-21] The free radicals generated in SCD cause extensive oxidative damage to various cellular components. Lipid peroxidation, driven by ROS, leads to the formation of oxidized lipids, which are recognized as damage-associated molecular patterns (DAMPs). These DAMPs activate innate immune receptors, further fueling the inflammatory response. Proteins and DNA are also targets of oxidative damage. Oxidized proteins can lose their functional properties or become modified in ways that trigger immune responses, while oxidative modifications to DNA can result in mutations and genomic instability. The cumulative effect of this oxidative damage disrupts cellular homeostasis and contributes to the pathophysiology of SCD.[22-24]

The oxidative stress induced by free radicals activates several inflammatory pathways. One key mechanism involves the activation of transcription factors such as nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1). These transcription factors drive the expression of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). These cytokines perpetuate the inflammatory response, leading to increased pain, swelling, and tissue damage. The chronic inflammation associated with SCD can also exacerbate endothelial dysfunction, leading to further complications such as vaso-occlusive crises.[25-27] Oxidative stress in SCD impairs endothelial function by reducing the bioavailability of nitric oxide (NO), a molecule crucial for maintaining vascular health. The decrease in NO levels and the subsequent oxidative damage to endothelial cells lead to an increased expression of adhesion molecules on the endothelial surface. This promotes the adhesion of leukocytes to the endothelium, facilitating their infiltration into tissues and contributing to the inflammatory process. The compromised endothelial function also plays a significant role in the vaso-occlusive events that characterize SCD, as the impaired blood flow further exacerbates oxidative stress and tissue damage.[28-29] The systemic effects of free radical-mediated oxidative stress and inflammation in SCD are profound. Pain crises, organ damage, and increased susceptibility to infections are common clinical manifestations. The oxidative damage to RBCs and the resulting hemolysis contributes to anemia and further perpetuate the cycle of oxidative stress. Organ damage, including complications such as acute chest syndrome and renal impairment, is driven by chronic inflammation and oxidative injury. Additionally, the heightened inflammatory response increases the risk of infections, as the immune system becomes dysregulated and less effective in combating pathogens.[30-32] Addressing the role of free radicals in SCD involves exploring therapeutic strategies that target oxidative stress and inflammation. Antioxidants such as N-acetylcysteine (NAC), vitamin E, and vitamin C have been studied for their potential to reduce oxidative damage and alleviate symptoms. Anti-inflammatory agents, including hydroxyurea, can also help manage inflammation and improve clinical outcomes. Emerging therapies, such as gene editing and novel pharmacological agents, offer promising avenues for addressing the underlying mechanisms of oxidative stress and inflammation in SCD.[33-35]

Mechanisms of Free Radical-Mediated Inflammation

In the context of Sickle Cell Disease (SCD), free radicals play a central role in driving inflammation and exacerbating disease pathology. The mechanisms by which free radicals mediate inflammation are intricate and involve multiple biological pathways that collectively contribute to the chronic inflammatory state characteristic of SCD.[36-37] The generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in SCD leads to significant oxidative damage to cellular macromolecules. Free radicals target lipids, proteins, and DNA, resulting in a cascade of cellular dysfunction. Lipid peroxidation is one of the primary outcomes of oxidative stress. ROS interact with lipid membranes, leading to the formation of reactive lipid peroxides. These lipid peroxides can generate additional free radicals, propagating a

cycle of oxidative damage. Oxidized lipids are recognized as damage-associated molecular patterns (DAMPs) by the immune system, triggering inflammatory responses. Proteins, when oxidized, can lose their functional integrity, become misfolded, or serve as neoantigens, further stimulating immune responses. DNA oxidation can lead to mutations and genomic instability, compounding cellular stress and promoting inflammation.[38-40] Free radical-induced oxidative damage activates several key inflammatory pathways. One major pathway involves the activation of transcription factors such as nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1). These transcription factors are sensitive to oxidative stress and regulate the expression of various pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Elevated levels of these cytokines perpetuate the inflammatory response by recruiting and activating immune cells, such as macrophages and neutrophils. This recruitment amplifies the inflammatory milieu and exacerbates tissue damage. Additionally, oxidative stress can influence the activation of inflammasomes, multi-protein complexes that drive the maturation and release of pro-inflammatory cytokines.[41-43]

The impact of free radicals extends to endothelial cells, which line the blood vessels and play a critical role in vascular homeostasis. In SCD, oxidative stress reduces the bioavailability of nitric oxide (NO), a molecule essential for maintaining endothelial function and regulating vascular tone. Nitric oxide is a potent vasodilator that prevents excessive platelet aggregation and leukocyte adhesion. When ROS levels are high, NO is scavenged, leading to decreased vasodilation and increased endothelial activation. This activation is marked by the upregulation of adhesion molecules, such as selectins and integrins, which facilitate the adhesion and infiltration of leukocytes into the endothelial layer. The consequent endothelial dysfunction promotes vaso-occlusive events and further contributes to the inflammatory response in SCD.[44-46] Oxidative stress not only affects endothelial cells but also has profound effects on immune cells. ROS and RNS influence the function and activation of various immune cells, including macrophages, neutrophils, and lymphocytes. These immune cells can become hyperactivated in response to oxidative stress, leading to the overproduction of inflammatory mediators. For instance, neutrophils release additional ROS and proteolytic enzymes in response to oxidative signals, exacerbating tissue damage and inflammation. Macrophages, when exposed to oxidative stress, can adopt a pro-inflammatory phenotype, characterized by increased production of cytokines and chemokines that further amplify the inflammatory response.[47-49] The initial oxidative damage and inflammatory responses create a self-perpetuating cycle of inflammation. As oxidative stress persists, it continues to drive the production of free radicals and inflammatory mediators. This ongoing cycle results in chronic inflammation, characterized by persistent activation of immune cells and sustained release of cytokines and chemokines. The chronic inflammatory environment further perpetuates tissue damage and contributes to the clinical manifestations of SCD, such as pain crises, organ damage, and increased infection risk.[50-51] Free radical-mediated inflammation does not occur in isolation but interacts with other pathological pathways. For example, oxidative stress can influence the activation of coagulation pathways, leading to increased thrombus formation and vascular occlusion. It can also affect metabolic pathways, altering cellular energy production and contributing to cellular dysfunction. The intersection of oxidative stress with these pathways highlights the complexity of inflammation in SCD and underscores the need for comprehensive therapeutic approaches.[52-53]

Impact on Clinical Manifestations

The role of free radicals in Sickle Cell Disease (SCD) extends far beyond the cellular and molecular levels, deeply influencing the clinical manifestations and overall disease burden. The chronic oxidative stress and inflammation driven by reactive oxygen species (ROS) and reactive

nitrogen species (RNS) lead to a variety of complications that define the clinical spectrum of SCD. One of the hallmark clinical manifestations of SCD is the vaso-occlusive crisis, commonly known as a pain crisis. These episodes are triggered by the obstruction of blood flow due to the sickling of red blood cells (RBCs). The resultant ischemia and tissue hypoxia create an environment of heightened oxidative stress. ROS and RNS generated during these crises contribute to endothelial damage, further promoting vaso-occlusion and exacerbating pain. The inflammation that accompanies these episodes amplifies the pain, making crises not only frequent but also more severe. The persistent oxidative stress during pain crises leads to a vicious cycle of inflammation and ischemia, significantly affecting the quality of life for affected individuals.[54-55] Chronic oxidative stress and inflammation have profound implications for organ function in SCD. The kidneys, liver, lungs, and spleen are particularly vulnerable to damage. In the kidneys, oxidative stress contributes to hemolysis-induced nephropathy, characterized by proteinuria and reduced renal function. The liver can suffer from chronic inflammation and oxidative injury, leading to conditions such as hepatomegaly and hepatic fibrosis. Pulmonary complications, including acute chest syndrome, are exacerbated by oxidative stress and inflammation, which contribute to lung damage and impaired gas exchange. In the spleen, repeated vaso-occlusive events and oxidative stress can lead to functional asplenia or splenic sequestration crises, increasing susceptibility to infections and further complicating disease management.[56]

The compromised immune function observed in SCD is partly a result of chronic oxidative stress and inflammation. Free radicals can impair immune cell function, including neutrophil and macrophage activity, reducing the body's ability to combat infections effectively. The spleen's dysfunction due to repeated vaso-occlusive events further increases the risk of bacterial infections, particularly with encapsulated organisms such as Streptococcus pneumoniae. This heightened infection risk not only complicates the clinical management of SCD but also contributes to increased morbidity and mortality among affected individuals.[57] Neurological manifestations of SCD, including stroke and cognitive impairments, are closely linked to oxidative stress. Free radicals and inflammation contribute to endothelial damage in cerebral vessels, increasing the risk of stroke and transient ischemic attacks. The chronic oxidative damage also affects neuronal tissues, potentially leading to cognitive deficits and neurological impairments. The interplay between oxidative stress and inflammation exacerbates these neurological complications, underscoring the need for interventions that target both oxidative damage and cerebrovascular health.[54] The cardiovascular system in SCD is significantly impacted by oxidative stress and inflammation. Endothelial dysfunction, driven by reduced nitric oxide (NO) availability and increased oxidative damage, leads to altered vascular tone and increased risk of thrombosis. The resulting cardiovascular complications can include hypertension, heart failure, and increased risk of thromboembolic events. The chronic nature of oxidative stress exacerbates these issues, making cardiovascular health a critical focus in the management of SCD.[55] Chronic hemolysis in SCD leads to persistent anemia, which is compounded by the increased oxidative stress and inflammation. The destruction of RBCs contributes to reduced hemoglobin levels, leading to fatigue, weakness, and reduced exercise tolerance. The oxidative damage to RBCs further accelerates their destruction, perpetuating the cycle of anemia and contributing to the overall fatigue and reduced quality of life experienced by individuals with SCD.[56] In pediatric patients with SCD, chronic oxidative stress and inflammation can impact growth and development. The anemia, pain crises, and frequent medical interventions associated with SCD can affect nutritional intake, physical activity, and overall health. This can lead to growth delays and developmental challenges, highlighting the importance of comprehensive management strategies that address both the clinical and developmental needs of children with SCD.[57]

Conclusion

Free radicals, through their role in oxidative stress and inflammation, are central to the pathophysiology of Sickle Cell Disease (SCD). The chronic production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) not only exacerbates cellular damage but also drives a cycle of inflammation that significantly impacts disease progression and clinical outcomes. This oxidative stress affects various aspects of SCD, including pain crises, organ damage, infection risk, and overall patient well-being.

The mechanisms by which free radicals mediate inflammation are complex and involve the oxidative damage of cellular macromolecules, activation of inflammatory pathways, and disruption of endothelial function. These processes lead to a variety of clinical manifestations, from acute pain episodes to chronic organ damage, and complicate the management of SCD. The interplay between oxidative stress and inflammation contributes to the severity and frequency of symptoms, impacting the quality of life for affected individuals.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Sbodio JI, Snyder SH, Paul BD. Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities. Antioxidants & Redox Signaling. 2019;30(11):1450-1499.
7. Kovacic P, Somanathan R. Redox processes in neurodegenerative disease involving reactive oxygen species. Current neuropharmacology. 2012;10(4):289-302.
8. La Rosa P, Petrillo S, Bertini ES, Piemonte F. Oxidative stress in DNA repeat expansion disorders: a focus on NRF2 signaling involvement. Biomolecules. 2020;10(5):702.
9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023;6(4):12-17.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
11. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
12. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
13. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
14. Renoux C, Joly P, Faes C, Mury P, Eglenen B, Turkay M, Yavas G, Yalcin O, Bertrand Y, Garnier N, Cuzzubbo D. Association between oxidative stress, genetic factors, and clinical severity in children with sickle cell anemia. The Journal of pediatrics. 2018; 195:228-235.
15. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, Pialoux V, Connes P, Gueye PM, Ndiaye Diallo R, Renoux C, Diagne I. Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. Antioxidants. 2020;9(9):863.

16. Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. International journal of molecular sciences. 2021;22(9):4642.
17. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
18. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
19. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
20. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
21. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
22. Silva M, Faustino P. From stress to sick (le) and back again–oxidative/antioxidant mechanisms, genetic modulation, and cerebrovascular disease in children with sickle cell anemia. Antioxidants. 2023;12(11):1977.
23. Deng M, Sun J, Peng L, Huang Y, Jiang W, Wu S, Zhou L, Chung SK, Cheng X. Scutellarin acts on the AR-NOX axis to remediate oxidative stress injury in a mouse model of cerebral ischemia/reperfusion injury. Phytomedicine. 2022; 103:154214.
24. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
25. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
26. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
27. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
28. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxidative medicine and cellular longevity. 2017;2017(1):2525967.
29. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
30. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
31. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
32. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
33. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):58-66.
34. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, Pialoux V, Connes P, Gueye PM, Ndiaye Diallo R, Renoux C, Diagne I. Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with

sickle cell anemia. Antioxidants. 2020;9(9):863.
35. Silva DG, Junior EB, de Souza Torres L, Júnior OR, de Castro Lobo C, Bonini-Domingos CR, De Almeida EA. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia. Blood Cells, Molecules, and Diseases. 2011;47(1):23-28.
36. Consoli V, Sorrenti V, Grosso S, Vanella L. Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions. Biomolecules. 2021;11(4):589.
37. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
38. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
39. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
40. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
41. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
42. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
43. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
44. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michaelokpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
45. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
46. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
47. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
48. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
49. Singh P, O'Toole TE, Conklin DJ, Hill BG, Haberzettl P. Endothelial progenitor cells as critical mediators of environmental air pollution-induced cardiovascular toxicity. American Journal of Physiology-Heart and Circulatory Physiology. 2021;320(4):H1440-55.
50. Al-Naama LM, Hassan MA, Mehdi JK. Association of erythrocytes antioxidant enzymes and their cofactors with markers of oxidative stress in patients with sickle cell anemia. Qatar medical journal. 2015;2015(2):14.
51. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
52. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.

53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
54. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
55. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
56. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free radical biology and medicine. 2008;44(8):1506-1528.
57. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100(9):1108.

Access this Article in Online	
Quick Response Code	Website: www.ijcrcps.com
	Subject: Haematology
DOI: 10.22192/ijcrcps.2024.11.08.003	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2024). Free Radical-Mediated Inflammation in Sickle Cell Disease: A Review . Int. J. Curr. Res. Chem. Pharm. Sci. 11(8): 20-28.
DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.08.003

